newsfilter
← Latest News
Business Wire·

Alpha Cognition Receives Issued U.S. Patent for ALPHA-1062 for Treatment of Traumatic Brain Injury

  • Alpha Cognition Inc. received U.S. Patent No. 12,589,099 from the USPTO on March 31, 2026.
  • The patent covers methods for treating confirmed & suspected traumatic brain injury (TBI) using ALPHA-1062.
  • Protection from the new patent extends through 2045.
  • CEO Michael McFadden stated the patent expands the company's platform beyond Alzheimer's disease.
  • The TBI market is estimated at $14 billion with no currently approved therapies.
  • ALPHA-1062 is being developed for moderate to severe Alzheimer's dementia in combination with memantine.
  • ZUNVEYL is a patented acetylcholinesterase inhibitor approved for Alzheimer's disease with minimal gastrointestinal side effects.
  • ZUNVEYL's active metabolite binds neuronal nicotinic receptors, specifically the alpha-7 subtype.
  • The news release includes forward-looking statements subject to risks regarding capital, efficacy, regulatory oversight, & commercialization.